BACKGROUND: Previous pharmacokinetic trials with standard levodopa formulations showed a different behaviour of levodopa degradation in plasma of patients with Parkinson's disease (PD) in various stages. OBJECTIVES: To investigate associations between levodopa plasma levels in relation to the scored intensity of PD. SUBJECTS AND METHODS: We administered water soluble 100 mg levodopa and 25 mg benserazide to 50 PD patients, taken off medication for at least 12 hours, and assessed the levodopa plasma concentrations during an 180 minutes period under standardised conditions. RESULTS: The computed area under the curve (AUC) values of levodopa plasma levels were significant higher in advanced PD patients. PD rating scores significantly correlated to the AUC outcomes and the maximum levodopa plasma concentration. CONCLUSIONS: Levodopa availability improves with progression of PD. This may result from deteriorated peripheral activity of levodopa metabolising enzymes or an increasing enteric dysfunction with subsequent better duodenal levodopa absorption or both.
BACKGROUND: Previous pharmacokinetic trials with standard levodopa formulations showed a different behaviour of levodopa degradation in plasma of patients with Parkinson's disease (PD) in various stages. OBJECTIVES: To investigate associations between levodopa plasma levels in relation to the scored intensity of PD. SUBJECTS AND METHODS: We administered water soluble 100 mg levodopa and 25 mg benserazide to 50 PDpatients, taken off medication for at least 12 hours, and assessed the levodopa plasma concentrations during an 180 minutes period under standardised conditions. RESULTS: The computed area under the curve (AUC) values of levodopa plasma levels were significant higher in advanced PDpatients. PD rating scores significantly correlated to the AUC outcomes and the maximum levodopa plasma concentration. CONCLUSIONS:Levodopa availability improves with progression of PD. This may result from deteriorated peripheral activity of levodopa metabolising enzymes or an increasing enteric dysfunction with subsequent better duodenal levodopa absorption or both.
Authors: G Arabia; M Zappia; D Bosco; L Crescibene; A Bagalà; L Bastone; M Caracciolo; M Scornaienghi; A Quattrone Journal: Neurol Sci Date: 2002-09 Impact factor: 3.307
Authors: Thomas Müller; Horst Baas; Jan Kassubek; Peter Riederer; Peter Paul Urban; Christoph Schrader; Heinz Reichmann; Dirk Woitalla; Manfred Gerlach Journal: J Neural Transm (Vienna) Date: 2015-11-14 Impact factor: 3.575